4559:TYO
Zeria Pharmaceutical Co Ltd
2 068,00 JPY
arrow_downward
−1,29%(−27,00) 1 D
20. nov., 15:30:00 GMT+9 · JPY
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for 4559 …
Åpne
2 068 JPY
Høy
2 088 JPY
Lav
2 058 JPY
Markedsverdi
103,65 mrd.
Snittvolum
132,53k
Volum
91,70k
Utbytte
2,42 %
Kvartalsvis utbytte
13 JPY
Første dato etter utbytte
30. mars 2027
P/E-forhold
8,54
52 u høy
2 434 JPY
52 u lav
1 895 JPY
EPS
242 JPY
Utestående aksjer
50,11 mill.
Antall ansatte
2k
Åpne
2 068 JPY
Høy
2 088 JPY
Lav
2 058 JPY
Markedsverdi
103,65 mrd.
Snittvolum
132,53k
Volum
91,70k
Utbytte
2,42 %
Kvartalsvis utbytte
13 JPY
Første dato etter utbytte
30. mars 2027
P/E-forhold
8,54
52 u høy
2 434 JPY
52 u lav
1 895 JPY
EPS
242 JPY
Utestående aksjer
50,11 mill.
Antall ansatte
2k
Nyhetssaker
Fra nettkilder og nyhetspartnere
ChartMill
·
for 1 time siden
S&P 500 Downward Gap Stocks in Nov. 20, 2026 Session
TradingView
·
for 52 minutter siden
S&P 500 is near a bottom, but breadth still shows final low is not there yet – BTIG’s Krinsky
Traders Union
·
for 25 minutter siden
S&P 500 P/E multiples range from 15.7x to 19.6x depending on EPS assumptions, Michael Kantro notes
FXEmpire
·
for 21 minutter siden
S&P 500 Price Forecast: AI Stock Selloff Puts 7,000 in Focus
Profil
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Om Zeria Pharmaceutical Co Ltd
Administrerende direktørSachiaki Ibe
Ansatte1,75k
Grunnlagt22. des. 1955
Hovedkontor-
SektorHealth Care
Bransje-
Nettstedzeria.co.jp